A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to confirm the safety profile of alemtuzumab 30 mg
(the US/European Union (EU) approved dose) in Japanese patients with relapsed or refractory
Chronic Lymphocytic Leukemia (CLL).